{"protocolSection": {"identificationModule": {"nctId": "NCT00772577", "orgStudyIdInfo": {"id": "CSPP100AUS07"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI \u2265 30) With Stage 2 Hypertension", "officialTitle": "An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI \u2265 30) With Stage 2 Hypertension", "acronym": "ATTAIN"}, "statusModule": {"statusVerifiedDate": "2011-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-08"}, "primaryCompletionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-10", "studyFirstSubmitQcDate": "2008-10-14", "studyFirstPostDateStruct": {"date": "2008-10-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-07", "resultsFirstSubmitQcDate": "2011-02-07", "resultsFirstPostDateStruct": {"date": "2011-03-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-03-08", "lastUpdatePostDateStruct": {"date": "2011-03-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI \u2265 30) with Stage 2 Hypertension"}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension, Obese, aliskiren, hydrochlorothiazide, systolic blood pressure, diastolic blood pressure, ramipril, stage 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 386, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Aliskiren Hydrochlorothiazide(HCTZ)", "interventionNames": ["Drug: Aliskiren Hydrochlorothiazide"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Ramipril", "interventionNames": ["Drug: Ramipril"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren Hydrochlorothiazide", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)", "description": "To assess the change in mean sitting systolic blood pressure (MSSBP) after 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg).", "timeFrame": "Baseline to week 8"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)", "description": "To evaluate the difference in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg).", "timeFrame": "Baseline to week 8"}, {"measure": "Percentage of Patients Achieving Blood Pressure Control During 8 Weeks", "description": "The percentage of patients achieving the Blood Pressure control (defined as patients achieving a MSSBP \\< 140 mm Hg and MSDBP \\< 90 mm Hg) during 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg). Data presented are cumulative. Cumulative refers to achieving blood pressure control before or at the 8 week visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.", "timeFrame": "8 weeks"}, {"measure": "Percentage of Responders (MSSBP < 140 mmHg or \u2265 20 mmHg Decrease From Baseline in MSSBP)", "description": "To compare the percentage of responders (as defined by patients with MSSBP \\< 140 mm Hg or a decrease from baseline \u2265 20 mm Hg) during 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg). Data presented are cumulative. Cumulative refers to achieving the response before or at the 8 week visit. If response occurred more than once, only the first occurrence was counted.", "timeFrame": "8 weeks"}, {"measure": "Change From Baseline in Mean Sitting Pulse Pressure (MSPP)", "description": "To compare the change in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg).", "timeFrame": "Baseline to week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.\n* Male or female outpatients, 18 years of age and older.\n* Patients with Stage 2 hypertension. Patients must have a MSSBP \u2265 160 mmHg and \\< 200 mmHg at Study Visit 5 (randomization).\n* Patients must have a BMI \u2265 30 kg/m2 but \u2264 45 kg/m2.\n\nExclusion Criteria:\n\n* Office blood pressure measured by cuff (MSDBP \u2265 110 mmHg and/or MSSBP \u2265 200 mmHg) at any visit.\n* Use of other investigational drugs within 30 days of enrollment, or 5 half-lives, which ever is longer.\n* Use of aliskiren and/or a fixed dose combination of aliskiren HCTZ or participation in a clinical trial that had aliskiren and/or aliskiren HCTZ as treatment within 30 days of Visit 1.\n* History of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class (ACE inhibitors or renin inhibitors) as the study drugs.\n* History or evidence of a secondary form of hypertension.\n* Refractory hypertension, defined as, unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmHg). Therapy with a fixed dose combination of two active substances represent two drugs.\n* Patients on 4 or more antihypertensive medications.\n* Long QT syndrome or QTc \\> 450 msec for males and \\> 470 msec for females at screening.\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigative Site", "city": "Beverly Hills", "state": "California", "country": "United States", "geoPoint": {"lat": 34.07362, "lon": -118.40036}}, {"facility": "Investigative Site", "city": "Santa Ana", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"facility": "Investigative Site", "city": "Conyers", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.66761, "lon": -84.01769}}, {"facility": "Investigative Site", "city": "Lexington", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Investigative Site", "city": "Columbia", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"facility": "Investigative Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info", "url": "http://www.bloodpressureresearch.com"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks"}, {"id": "FG001", "title": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "193"}, {"groupId": "FG001", "numSubjects": "193"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "170"}, {"groupId": "FG001", "numSubjects": "170"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "23"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Abnormal laboratory values", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks"}, {"id": "BG001", "title": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "193"}, {"groupId": "BG001", "value": "193"}, {"groupId": "BG002", "value": "386"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.4", "spread": "11.15"}, {"groupId": "BG001", "value": "54.4", "spread": "10.90"}, {"groupId": "BG002", "value": "54.9", "spread": "11.02"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "206"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "180"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)", "description": "To assess the change in mean sitting systolic blood pressure (MSSBP) after 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg).", "populationDescription": "Intent-to-treat population (consisted of all patients who received at least one dose of study medication and had at least one valid post baseline assessment of primary efficacy variable). Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to week 8", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks"}, {"id": "OG001", "title": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "167.0", "spread": "7.05"}, {"groupId": "OG001", "value": "168.2", "spread": "7.86"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "138.9", "spread": "16.56"}, {"groupId": "OG001", "value": "151.6", "spread": "17.44"}]}]}, {"title": "Change from baseline to week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.1", "spread": "15.54"}, {"groupId": "OG001", "value": "-16.6", "spread": "14.76"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)", "description": "To evaluate the difference in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg).", "populationDescription": "Intent-to-treat population (consisted of all patients who received at least one dose of study medication and had at least one valid post baseline assessment of primary efficacy variable). Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to week 8", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks"}, {"id": "OG001", "title": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "94.3", "spread": "8.41"}, {"groupId": "OG001", "value": "96.3", "spread": "8.48"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "84.2", "spread": "9.80"}, {"groupId": "OG001", "value": "92.7", "spread": "11.07"}]}]}, {"title": "Change from baseline to week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.1", "spread": "9.04"}, {"groupId": "OG001", "value": "-3.6", "spread": "9.48"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Blood Pressure Control During 8 Weeks", "description": "The percentage of patients achieving the Blood Pressure control (defined as patients achieving a MSSBP \\< 140 mm Hg and MSDBP \\< 90 mm Hg) during 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg). Data presented are cumulative. Cumulative refers to achieving blood pressure control before or at the 8 week visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.", "populationDescription": "Intent-to-treat population (consisted of all patients who received at least one dose of study medication and had at least one valid post baseline assessment of primary efficacy variable).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks"}, {"id": "OG001", "title": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "63.7"}, {"groupId": "OG001", "value": "30.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Responders (MSSBP < 140 mmHg or \u2265 20 mmHg Decrease From Baseline in MSSBP)", "description": "To compare the percentage of responders (as defined by patients with MSSBP \\< 140 mm Hg or a decrease from baseline \u2265 20 mm Hg) during 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg). Data presented are cumulative. Cumulative refers to achieving the response before or at the 8 week visit. If response occurred more than once, only the first occurrence was counted.", "populationDescription": "Intent-to-treat population (consisted of all patients who received at least one dose of study medication and had at least one valid post baseline assessment of primary efficacy variable).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks"}, {"id": "OG001", "title": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87.9"}, {"groupId": "OG001", "value": "63.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Pulse Pressure (MSPP)", "description": "To compare the change in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with aliskiren HCTZ (150/12.5 mg, 300/25 mg) versus ramipril (5 mg, 10 mg).", "populationDescription": "Intent-to-treat population (consisted of all patients who received at least one dose of study medication and had at least one valid post baseline assessment of primary efficacy variable). Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to week 8", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks"}, {"id": "OG001", "title": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.7", "spread": "10.44"}, {"groupId": "OG001", "value": "71.9", "spread": "9.85"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "54.7", "spread": "13.87"}, {"groupId": "OG001", "value": "58.9", "spread": "13.98"}]}]}, {"title": "Change from baseline to week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.0", "spread": "12.14"}, {"groupId": "OG001", "value": "-13.0", "spread": "12.12"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "8 weeks", "eventGroups": [{"id": "EG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks", "seriousNumAffected": 4, "seriousNumAtRisk": 193, "otherNumAffected": 14, "otherNumAtRisk": 193}, {"id": "EG001", "title": "Ramipril", "description": "Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 193, "otherNumAffected": 17, "otherNumAtRisk": 193}], "seriousEvents": [{"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 193}]}, {"term": "Pollakiuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 193}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 193}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 193}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "D000017257", "term": "Ramipril"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}], "browseLeaves": [{"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}